Business Description
Exelixis Inc
NAICS : 541714
SIC : 8731
ISIN : US30161Q1040
Share Class Description:
EXEL: Ordinary SharesTotal Employee Number:
1,077Compare
Compare
Traded in other countries / regions
EXEL.USA0IJO.UKEX9.Germany1EXEL.ItalyE2XE34.Brazil Index Membership
Russell 1000Russell 3000 IPO Date
2000-04-11Description
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.06 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | 0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 15.06 | |||||
Beneish M-Score | -3.04 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 18.4 | |||||
3-Year EBITDA Growth Rate | 68.4 | |||||
3-Year EPS without NRI Growth Rate | 55.4 | |||||
3-Year FCF Growth Rate | 63.1 | |||||
3-Year Book Growth Rate | 2.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 17.59 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.32 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.28 | |||||
9-Day RSI | 55.87 | |||||
14-Day RSI | 52.71 | |||||
3-1 Month Momentum % | 14.9 | |||||
6-1 Month Momentum % | 26.63 | |||||
12-1 Month Momentum % | 49.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.46 | |||||
Quick Ratio | 3.38 | |||||
Cash Ratio | 2.32 | |||||
Days Inventory | 109 | |||||
Days Sales Outstanding | 46.16 | |||||
Days Payable | 122.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 6.8 | |||||
Shareholder Yield % | 8.39 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 96.48 | |||||
Operating Margin % | 40.73 | |||||
Net Margin % | 35.33 | |||||
EBITDA Margin % | 41.89 | |||||
FCF Margin % | 47.55 | |||||
OCF Margin % | 48.58 | |||||
ROE % | 42.46 | |||||
ROA % | 32.03 | |||||
ROIC % | 48.91 | |||||
3-Year ROIIC % | 1986.92 | |||||
ROC (Joel Greenblatt) % | 231.33 | |||||
ROCE % | 42.81 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.97 | |||||
Forward PE Ratio | 16.67 | |||||
PE Ratio without NRI | 15.42 | |||||
Shiller PE Ratio | 38.28 | |||||
Price-to-Owner-Earnings | 17.12 | |||||
PEG Ratio | 0.33 | |||||
PS Ratio | 5.96 | |||||
PB Ratio | 7.28 | |||||
Price-to-Tangible-Book | 7.55 | |||||
Price-to-Free-Cash-Flow | 12.59 | |||||
Price-to-Operating-Cash-Flow | 12.32 | |||||
EV-to-EBIT | 12.8 | |||||
EV-to-Forward-EBIT | 11.49 | |||||
EV-to-EBITDA | 12.45 | |||||
EV-to-Forward-EBITDA | 11.09 | |||||
EV-to-Revenue | 5.21 | |||||
EV-to-Forward-Revenue | 5.01 | |||||
EV-to-FCF | 10.96 | |||||
Price-to-GF-Value | 1.18 | |||||
Price-to-Projected-FCF | 1.68 | |||||
Price-to-Median-PS-Value | 1.03 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.62 | |||||
Price-to-Graham-Number | 2.27 | |||||
| Price-to-Net-Current-Asset-Value | 22.39 | |||||
| Price-to-Net-Cash | 71.01 | |||||
Earnings Yield (Greenblatt) % | 7.81 | |||||
FCF Yield % | 8.66 | |||||
Forward Rate of Return (Yacktman) % | 23.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EXEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exelixis Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,435.92 | ||
| EPS (TTM) ($) | 3.18 | ||
| Beta | 0.3429 | ||
| 3-Year Sharpe Ratio | 1.09 | ||
| 3-Year Sortino Ratio | 2.14 | ||
| Volatility % | 24.81 | ||
| 14-Day RSI | 52.71 | ||
| 14-Day ATR ($) | 1.743564 | ||
| 20-Day SMA ($) | 53.904 | ||
| 12-1 Month Momentum % | 49.04 | ||
| 52-Week Range ($) | 33.755 - 57.57 | ||
| Shares Outstanding (Mil) | 247.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exelixis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exelixis Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-10 17:00 | In 175 days | ||
| Annual report for 2026 | 2027-02-10 | In 174 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-10 | In 174 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 17:00 | In 77 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 76 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | 56.00 (+1.71%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 56.00 (+1.71%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:40 | 51.74 (-1.91%) | ||
| Guidance call for 2026 | 2026-06-03 11:05 | 48.54 (-3.46%) | ||
| Bernstein 42nd Annual Strategic Decisions Conference | 2026-05-27 15:30 | 49.98 (-1.13%) |
Show
Entries
Exelixis Inc Frequently Asked Questions
What is Exelixis Inc(EXEL)'s stock price today?
The current price of EXEL is $53.97. The 52 week high of EXEL is $57.57 and 52 week low is $33.76.
When is next earnings date of Exelixis Inc(EXEL)?
The next earnings date of Exelixis Inc(EXEL) is 2026-11-04 Est..
Does Exelixis Inc(EXEL) pay dividends? If so, how much?
Exelixis Inc(EXEL) does not pay dividend.
Guru Commentaries on NAS:EXEL
No articles.
Press Release
Articles on Exelixis Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers